Health
Study finds some antibody therapies cannot combat new COVID variants – European Pharmaceutical Review
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against new SARS-CoV-2 variants, while other antibodies were not.
Posted: 28 January 2021 | Hannah Balfour (European Pharmaceutical Review) | No comments yet
In vitro neutralisation assays show REGEN-COV and AZD7442 are effective against the new SARS-CoV-2 variants, while other antibody therapies, including Eli Lillys bamlanivimab, were not.
New research suggests that new variants of the SARS-CoV-2 virus are more resistant to neutralisation with antibody therapies, including convalescent plasma and vaccinee sera. According to the authors of the paper, currently…
-
Business22 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News21 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
General16 hours agoDeveloper warns wind energy capacity may not be ready by WA coal deadline
-
Noosa News18 hours agoTips to improve engagement – Proctor